Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics, Inc.    SRPT

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Number of employees : 743 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Eteplirsen Injection and Golodirsen Injection301.03100%380.83100% +26.51%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States301.03100%380.83100% +26.51%
Managers
NameAgeSinceTitle
Douglas Ingram562017President, Chief Executive Officer & Director
M. Behrens662015Chairman
Joseph Bratica552020VP, Controller, CFO & Chief Accounting Officer
Gilmore O’Neill, Dr.542018Chief Medical Officer & Senior Vice President
Hans Lennart Rudolf Wigzell, Dr.802012Independent Director
Richard Jon Barry602015Independent Director
Claude Nicaise, Dr.662015Independent Director
Mary Ann Gray, Dr.662018Independent Director
John Martin672020Independent Director
David Tyronne Howton472013Secretary, Senior Vice President & General Counsel
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,913,045 75,120,232 95.2% 0 0.0% 95.2%
Shareholders
NameEquities%
The Vanguard Group, Inc. 6,969,060 8.88%
Capital Research & Management Co. (Global Investors) 6,711,324 8.55%
Fidelity Management & Research Co. LLC 5,522,086 7.03%
Sands Capital Management LLC 4,339,256 5.53%
Janus Capital Management LLC 3,617,829 4.61%
Richard Jon Barry 3,129,140 3.99%
Jennison Associates LLC 2,605,072 3.32%
BlackRock Fund Advisors 2,036,665 2.59%
Sabby Capital LLC 2,014,787 2.57%
SSgA Funds Management, Inc. 1,899,252 2.42%
Holdings
NameEquities%Valuation
LYSOGENE (LYS) 1,140,7286.96%2,478,175 USD
Company contact information
Sarepta Therapeutics, Inc.
215 First Street
Suite 415
Cambridge, MA 02142

Phone : +1.857.242.4000
Web : http://www.sareptatherapeutics.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS, INC.7.83%10 981
GILEAD SCIENCES, INC.-7.62%75 249
VERTEX PHARMACEUTICALS3.54%58 953
REGENERON PHARMACEUTICALS36.90%54 255
WUXI APPTEC CO., LTD.56.53%37 916
BIONTECH SE224.65%26 484
BEIGENE, LTD.72.47%26 060
GENMAB A/S56.53%24 374
ARGENX SE63.65%13 301
MYOKARDIA, INC.208.58%11 993
MIRATI THERAPEUTICS, INC.80.46%11 692
HUALAN BIOLOGICAL ENGINEERING INC.49.79%11 555
NEUROCRINE BIOSCIENCES, INC.-11.10%8 928
ASCENDIS PHARMA A/S18.26%8 788
ULTRAGENYX PHARMACEUTICAL INC.186.63%8 099
DENALI THERAPEUTICS INC.251.72%7 347
ACCELERON PHARMA INC.122.09%7 095
BIOCON LIMITED46.19%6 873
KODIAK SCIENCES INC.87.63%6 800
ARROWHEAD PHARMACEUTICALS, INC.-0.69%6 473
PEPTIDREAM INC.-10.36%6 261